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Abstract (250) 27 
The cytokine interleukin 6 (IL-6), has been linked to the pathogenesis of Alzheimer’s disease (AD). This 28 
is the first study to investigate the genetic and epigenetic interactions in the control of IL-6 in human 29 
brain and its relation to AD neuropathology in prefrontal cortex tissues from AD and controls genotyped 30 
for the SNP -174 C/G rs1800795, a polymorphic CpG in which the G allele creates a CpG site. Within CC 31 
homozygotes there were significantly higher brain levels of IL-6 protein compared to G allele carriers. 32 
The C allele that resulted in an absence of methylation at a CpG also associated with significant changes 33 
in methylation at neighbouring CpGs. Furthermore, there were differential significant differences in 34 
methylation between CC and CG/GG at CpG sites in the AD and control groups. That DNA methylation 35 
was shown to be altered in the brains by the presence of rs1800795, which further correlated with 36 
protein levels suggests the presence of a polymorphic CpG and genetic-epigenetic interactions in the 37 
regulation of IL-6 in the prefrontal cortex within AD brains.  38 
 39 
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1. Introduction 43 
Interleukin 6 (IL- 6) is a cytokine with both pro- and anti-inflammatory functions and shows both neuro-44 
protective and -degenerative properties within the brain (Baune et al., 2012) IL-6 has a major role in 45 
chronic inflammation, and elevated levels are found in many inflammatory diseases (Gabay, 2006) 46 
including cognitive decline and Alzheimer’s disease (AD) (Bradburn et al., 2018; Koyama et al., 2013; Lai 47 
et al., 2017). The development of β-amyloid plaques and tau within AD can induce microglia and 48 
astrocytes to secrete immune factors such as IL-6 and vice versa, levels of IL-6 are thought to increase 49 
the development of β-amyloid plaques and tau tangles  with increased levels of IL-6 found in the 50 
formation of β-amyloid plaques and phosphorylated tau (Hüll et al., 1996; Quintanilla et al., 2004). The 51 
IL-6 polymorphism rs1800795, located in the promoter region -174 bp upstream of the transcriptional 52 
start site has been shown to regulate IL-6 expression (Falleti et al., 2010). However, the results of 53 
studies regarding the activity and effects of the polymorphism on plasma levels of these mediators and 54 
susceptibility to different diseases are contradictory. Rea et al. (Rea et al., 2003) in a study of 55 
octogenarian and nonagenarian subjects found that participants homozygotes for the C allele 56 
presented with higher plasma IL-6 levels, a finding supported by another study on individuals older than 57 
80 years (Bruunsgaard et al., 2004). In contrast, a study of elderly women reported that the G allele was 58 
associated with higher plasma IL-6 levels (Pereira et al., 2011). A meta-analysis of plasma IL-6 levels in 59 
healthy individuals found no significant association with this variant (Huang et al., 2013). In regard to 60 
transcriptional activity, in silico analysis and qRT-PCR on neuroblastoma specimens showed that the CC 61 
genotype correlated with higher level of IL-6 expression (Totaro et al., 2013). In regard to possible 62 
mechanisms, it has been demonstrated that the G>C single nucleotide polymorphism (SNP) affects 63 
GATA1 binding to the IL-6 promoter, thereby linking this SNP to differential risk of inflammation-related 64 
diseases (Cole et al., 2010). Furthermore, the rs1800795 is a polymorphic CpG with the G>C disrupting 65 
a CpG site that could potentially be methylated to allow allele-specific epigenetic control. 66 
The IL-6 −174 G/C polymorphism has been widely investigated in relation to the risk of inflammatory-67 
related diseases. Four meta-analysis studies have investigated the -174 G/C  polymorphism and the risk 68 
of AD. Three reported a reduced risk with the C allele in CC homozygotes (Dai et al., 2012; Han et al., 69 
2011; Qi et al., 2012) though, a more recent (2016) meta-analysis revealed that all genetic models 70 
(homozygote, CC vs. GG; heterozygote, GC vs. GG; dominant CC/GC vs. GG; recessive models, CC vs. 71 
GC/GG) were not associated with the risk of AD (Mun et al., 2016). A study investigating serum and 72 
brain IL-6 protein levels in AD patients genotyped for rs1800795, found significantly increased levels of 73 
plasma IL-6 in homozygous C individuals compared to heterozygous and those homozygous for the G 74 
allele, but only in AD patients and not controls. The group also reported an increase in IL-6 in the mid 75 
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frontal cortex (Licastro et al., 2003) in participants homozygous for the C allele, suggesting a possible 76 
impact of the AD pathology on IL-6 allele-specific regulation. 77 
The expression of IL-6 is known to be regulated by epigenetic mechanisms including DNA methylation. 78 
Nile et al. (Nile et al., 2008) found significantly lower DNA methylation within the IL-6 promoter in blood 79 
cells of patients suffering from rheumatoid arthritis. Dandrea et al. (Dandrea et al., 2009) found that 80 
the in vitro DNA demethylation, using 5-aza-2´-deoxycytidine, induced IL-6 expression that correlated 81 
reduced methylation in the IL-6 promoter. Poplutz et al. (Poplutz et al., 2014) in differentiating 82 
monocytic HL-60 cells showed that changes in methylation at CpGs in the IL-6 promoter correlated with 83 
IL-6 expression. Investigating AD brains, Nicolia et al. (Nicolia et al., 2017) showed a progressive 84 
decrease in DNA methylation at the IL-6 promoter with disease progression. However, fFew studies 85 
have investigated together the epigenetic, genetic, transcriptional and translational regulation of this 86 
cytokine within the brain in relation to AD. If rs1800795 acts as a polymorphic CpG then it would be 87 
important to investigate if it plays a role in IL-6 regulation in AD. 88 
The aim of this study was to investigate mechanisms underlying the role of rs1800795 in the regulation 89 
of IL-6 within the brain and to understand how this may be a risk factor for AD. We studied human 90 
prefrontal cortex tissue for Il-6 protein levels, gene expression and promoter DNA methylation to test 91 
the hypothesis that G and C alleles differentially regulate the activity of IL-6 expression to understand 92 
the possible role of allele-specific regulation of IL-6 in AD. 93 
2. Materials and methods  94 
2.1 Study population 95 
Fresh, frozen tissue was taken from superior frontal gyrus (Brodmann area 8) from donors through the 96 
Manchester Brain Bank. Ethical approval was granted from the Manchester Brain Bank Committee. 97 
Donors were participants of a large prospective cognitive ageing cohort known as The University of 98 
Manchester Age and Cognitive Performance Research Cohort (Rabbitt et al., 2004; Robinson et al., 99 
2018) and included all those with brain material and available neuropathological data. All participants 100 
were white British (Supplementary Table 1). Stratification into AD neuropathology and control groups 101 
were based on neurofibrillary tangle stage (Braak), and neuritic plaque score (CERAD). 102 
2.2 Genotyping 103 
DNA  were extracted from the pre-frontal cortex samples, as described previously (Bradburn et al., 104 
2018), and genotyped for the rs1800795 polymorphism using the Kompetitive Allele-Specific PCR 105 
(KASP) assay (LGC Ltd) in reaction volumes of 10 µl together with 5ng of DNA. This was run on a 106 
Stratagene MX3000P qPCR machine (Agilent) and results analysed using the MXPro software. 107 
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2.3 Protein quantification 108 
Approximately 100 mg of prefrontal cortex tissue was lysed with RIPA buffer (Sigma – Aldrich) 109 
containing a protease inhibitor cocktail (Sigma – Aldrich). Protein concentration of IL-6 was determined 110 
using the high sensitivity human IL-6 ELISA kit (Abcam).  111 
2.4 Gene expression analysis 112 
Brain tissue (~30 mg) was extracted for RNA using TRIsure™ (Bioline, UK), and quantified using the 113 
Nanodrop 2000c (Thermo Scientific, Wilmington, USA). RNA samples were analyzed using the Agilent 114 
2100 Bioanalyzer with RNA 6000 kits to give RNA integrity numbers (RIN values). The Tetro cDNA 115 
synthesis kit (Bioline, UK) was used to reverse transcribe total RNA (2 μg) using random hexamers. 116 
Relative gene expression was analysed using qPCR with SensiFASTTM SYBR® Lo-ROX kit (Bioline) with 117 
primers for IL-6 (F: GGTACATCCTCGACGGCATCT; R: GTGCCTCTTTGCTGCTTTCAC), β-ACTIN (F: 118 
CATCCTCACCCTGAAGTACC; R: ATAGCAACGTACATGGCTGG) and GAPDH (F: CCGCATCTTCTTTTGCGTCG; 119 
R: TGGAATTTGCCATGGGTGGA) that were run on a Stratagene Mx3000P qPCR system (Agilent) in 120 
duplicate. Relative gene expression, accounting for primer efficiencies and normalised to GAPDH and 121 
β-ACTIN, were determined using a geometric averaging method described by Vandesompele et al 122 
(Vandesompele et al., 2002). 123 
2.5 DNA methylation analysis 124 
Genomic DNA was extracted using the Isolate II Genomic DNA kit (Bioline) and 500 ng bisulfite-125 
converted using the EpiMark Bisulfite Conversion Kit (New England Biolabs). Primers were designed 126 
using the Pyromark Assay design software (Qiagen)used to amplify regions of the IL-6 promoter (F – 127 
AAAAAGAAAGTAAAGGAAGAGTGG-Biotinylated; R: CCTCAAACATCTCCAATCCTATATTTA; S: 128 
AAACCTTATTAAAATTATACAATAT). PCRs were performed  using MyTaq HS mix PCR reagents (Bioline) 129 
with the following conditions: initial denaturation of 1min 95C; 49 cycles of 95C for 15sec, 52.6C for 130 
15sec, 72C for 10s; final extension of 72C for 5min. The IL-6 promoter region analysed (>hg38_dna 131 
range=chr7:22726826-22727526 5'pad=200 3'pad=500) contained 4 CpG sites or 3 depending on 132 
genotype (see Supplementary Figure 1). Amplicons were processed on the Qiagen Q24 Workstation and 133 
sequenced using the Sequecing primer AAACCTTATTAAAATTATACAATAT designed to analyse the region 134 
AACRTCCTTTAACATAACAA AACACAACTAAAAAAAAAAAT. Assays were performed in duplicate on the 135 
Qiagen Q24 pyrosequencer and included .a control for complete bisulphite conversion (Dejeux et al., 136 
2009).. 137 
 138 
2.6 Statistical analyses 139 
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The SPSS statistics software package (v25.0 for Windows; SPSS, Chicago, IL) was used for statistical 140 
analyses. Data was tested for normality using the Shapiro–Wilk test. Data determined to be normally 141 
distributed was presented as mean ± standard deviation (SD) or median and 25th-75th percentiles if not 142 
normally distributed. IL-6 protein and IL-6 expression levels were analysed using a Mann-Whitney U 143 
test. A Kruskal Wallis test was used to analyse the significance of IL-6 protein levels between the 144 
neuropathological hallmarks CERAD and BRAAK.Methylation percentage among CpG sites were 145 
analysed using an independent T-test to compare between control and AD that were  defined as: 146 
Control (0-A CERAD; 0-2 Braak) AD (B CERAD; 3-5 Braak): excluding brains that did not fall into the 147 
catagories due to other pathologies and diagnoses (see Supplemental Table 1)  there were n=17 control 148 
brains and n=27 AD samples. Correlations between protein, DNA methylation and gene expression of 149 
IL-6 were determined using Spearman’s correlation test. A significance threshold of P=<0.05 was used. 150 
3. Results  151 
3.1 Study population  152 
Clinical and pathological characteristics of the study population can be found in Table 1. IL-6 protein 153 
levels were compared between measures of AD neuropathology including BRAAK,THAL and CERAD. 154 
Importantly one data point with a value of 128.98 pg/mg (6x above the S.D.) was removed from all 155 
analyses. Samples that could not be classified into various staging were omitted from the anaysis. This 156 
revealed no significance differences between IL-6 protein levels between control and AD, and BRAAK 157 
(p=0.564), THAL (p = 0.320) or CERAD (p = 0.719) staging (Figure 1). IL-6 mRNA levels also did not differ 158 
between control and AD groups (p=0.713) (Figure 2).  159 
 160 
3.2 rs1800795 polymorphism and IL-6 protein and mRNA levels 161 
Levels of IL-6 total protein and relative IL-6 gene expression were compared between the two different 162 
genotypes. This revealed that IL-6 protein levels in C homozygotes were significantly higher than the G 163 
allele carriers p=0.034 (CC (n=21) compared to CG/GG (n= 41)). IL-6 gene expression however did not 164 
differ between genotypes p=0.459 (Figure 3); importantly, one data point with a value of 29.53 (4x 165 
above the S.D.) was removed from the analysis.  166 
 167 
3.3 DNA methylation at the IL-6 promoter 168 
IL-6 promoter methylation in the brains of homozygous C and heterozygous carriers (that contain an 169 
extra CpG (site 2)) was compared. While CpG site 1 methylation did not significantly differ (p=0.708) 170 
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between genotype groups, methylation at CpG site 3 was significantly lower in the G carriers (p=0.0003, 171 
while methylation at CpG site 4 was significantly higher in G carriers (p=<0.0001) (Figure 4). This 172 
suggests that the G allele influences DNA methylation at the IL-6 promoter. When correlating CpG2 173 
methylation in G carriers (the genotype that produces a CpG), we observed that there was no significant 174 
association with either IL-6 expression ((p=0.445; n=28) or protein levels (p=0.629; n=29). CpG 2 175 
methylation was further compared between controls and AD patients and again no correlations were 176 
observed in protein and IL-6 expression levels in either control or AD groups (p=0.805 and 0.219, 177 
respectively). Levels of CpG methylation at the IL-6 promoter were further analysed using an 178 
independent t-test for differences between controls and AD brains. Methylation between the control 179 
and AD groups did not significantly differ at CpG sites 1 (p=0.241), 2 (p=0.309) and 4 (p=0.625), though 180 
CpG 3 showed a non-significant trend towards reduced methylation in AD (P=0.052) (Figure 5). 181 
Spearman correlations between IL-6 protein levels and methylation at each CpG site for each genotype 182 
(CC n=15) found no correlations at CpGs 1 (p=0.436), 3 (p=0.681) and 4 (p=0.383). Similarly, there were 183 
no associations between IL-6 protein levels in CpG site 1 (p=0.743), 3 (p=0.666) and 4 (p=0.530) in the 184 
CG/GG genotype group (n=29). This indicates that methylation levels are not correlated with protein 185 
levels when stratified by genotype. A comparison was preformed between each CpG site and IL-6 gene 186 
expression levels stratified into genotype to determine if methylation levels correspond to the levels of 187 
expression. No correlations were found between IL-6 gene expression with CpG site 1 (p = 0.621), 3 188 
(p=0.823) and 4 (p=0.784) in the CC genotype group (n=13) and no associations were found between 189 
IL-6 gene expression levels in CpG site 1 (p=0.530), 3 (p=0.445) and 4 (p=0.09) in the CG/GG genotype 190 
group (n=28). This shows that IL-6 gene expression is not regulated by DNA methylation within the 191 
different genotypes. 192 
Considering genotype influenced methylation at CpG sites 3 and 4 and CpG 3 showed a non-193 
significant trend to reduced methylation in the AD brains, we performed an Anova between AD and 194 
control brains for DNA methylation at these two sites between the genotypes. This revealed significant 195 
differences in methylation between CC and CG/GG at CpG sites 3 and 4 in the AD group (p=0.003 and 196 
0.000) and CpG site 4 in the control group (p=0.002) suggesting that the rs1800795 genotype regulates 197 
DNA methylation at neighbouring CpGs in the presence of AD pathology.  198 
 199 
4. Discussion  200 
In human prefrontal cortex we found that the rs1800795 polymorphism was associated with differential 201 
methylation of the IL-6 promoter and IL-6 protein levels. Specifically, we found higher levels of IL-6 202 
protein in C homozygous individuals compared to those carrying at least one copy of the G allele. This 203 
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suggests levels of IL-6 in brain tissues may be regulated by the IL-6 rs1800795 polymorphism. 204 
Importantly, the G allele produces a CpG site that we found can be methylated and influences local 205 
DNA methylation at CpG sites 3 and 4 in the IL-6 promoter, indicating that the rs1800795 genotype has 206 
an effect upon epigenetic regulation of the gene in the prefrontal cortex. Finally, we found reduced and 207 
increased levels of DNA methylation at CpGs 3 and 4 respectively in AD brains compared to control 208 
suggesting a gene-environment interaction between the rs1800795 polymorphism and epigenetic 209 
regulation of IL-6. IL-6 has been detected in the brains of AD patients, particularly in those with early 210 
stages of amyloid deposition and plaque formation (Gruol and Nelson, 1997). Further, the expression 211 
levels of IL-6 mRNA, from a study in transgenic mouse brains, were found to increase during AD 212 
pathology (López-González et al., n.d.). In our studies we did not find such a pattern. However, a 213 
previous study on a group of 46 AD brains showed that levels of IL-6 were higher in CC genotypes 214 
compared to CG and GG (Licastro et al., 2003), similar to our data. This may account for the similarity 215 
between AD and control if genotype is not considered. However,  when we did control for genotype 216 
there were still no differences in IL-6 expression between control and AD brains (data not shown).  In 217 
addition, RNA integrity numbers (RIN), used to measure the quality of the mRNA, were on the lower 218 
side in this study and this related to variations in postmortem times (Supplementary Table 1). This may 219 
also have impacted the RNA analyses.  220 
Our finding that IL-6 protein levels were lower in those prefrontal cortex samples in individuals with 221 
genotypes containing the G allele is in agreement with the only previous study that has tested this 222 
(Licastro et al., 2003) suggesting  a regulatory role of this polymorphism. Additional studies of serum 223 
from juvenile chronic arthritis patients (Fishman et al., 1998), LPS-stimulated leukocytes (Rivera-Chavez 224 
et al., 2003), and 2 genetically different cell lines (Terry et al., 2000) have indicated that rs1800795 225 
might affect IL-6 gene regulation by modulating unspecified transcription factors. Cole and colleagues 226 
(2010) (Cole et al., 2010) using computational prediction of GxE to investigate a 1000bp region of the 227 
IL-6 promoter reported rs1800795 to be the sole functionally active regulatory SNP that was predicted 228 
to show high-affinity binding of the GATA-1 transcription factor that would be abrogated by the G>C 229 
transversion. This was supported using allele-specific chromatin immunoprecipitation assays in 230 
macrophages. Although binding was at very low levels at the IL-6 GATA-1 element, this was significantly 231 
increased for the G allele compared to the C allele in response to norepinephrine and this was further 232 
mediated by beta-adrenergic activation of the protein kinase A (PKA) signalling pathway. This study also 233 
used luciferase reporter assays in B lymphocytes to show that GATA-1 repressed IL-6 expression 234 
following the addition of norepinephrine. Other independent studies have shown that GATA-1 at other 235 
genes in neuronal cells can act as a repressor, for example at the γ-secretase gene in Down Syndrome 236 
brains with AD pathology (Chu et al., 2016). Interestingly, a published abstract reported increased levels 237 
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of GATA-1 protein in prefrontal cortex of AD brains compared to controls (Wang et al., 2014). 238 
Furthermore, Amyloid β-peptide has been shown to inhibit PKA signalling pathways (Vitolo et al., 2002) 239 
that is itself regulated by beta-adrenergic signalling (Bussiere et al., 2017). 240 
The 174G>C IL-6 promoter polymorphism (rs1800795) has been associated with numerous 241 
inflammatory-related diseases including systemic onset juvenile arthritis, systemic lupus erythamatosis, 242 
Sjögren's syndrome, AD, type II diabetes mellitus and cardiovascular disease (Bruunsgaard et al., 2004; 243 
Dai et al., 2012; Fishman et al., 1998; Hulkkonen et al., 2001; Humphries et al., 2001; Schotte et al., 244 
2001). Though studies have documented a direct functional effect of this variant on promoter activity, 245 
the association of this polymorphism with IL-6 levels is not consistent, with some studies showing higher 246 
IL-6 levels with the C allele (e.g. in plasma following coronary bypass (Brull et al., 2001), some with G 247 
(e.g  in patients with multivessel coronary artery (Burzotta et al., 2001)) and some with neither (e.g. in 248 
patients with and without coronary artery disease (Nauck et al., 2002)). One possible explanation for 249 
these differences may be that additional functional variation may exist from allele-dependent 250 
epigenetic modifications. Another aspect to consider is that though methylated cytosines are found 251 
primarily at CpG dinucleotides, they are also found at non-CpG sites (CpH), such as CpA, CpT, and 252 
CpC. Although the function and mechanisms of this type of methylation are not fully understood, 253 
studies show the presence of CpH methylation in human brains, and in vitro studies show mCpHs can 254 
repress transcription (Guo et al., 2014). As our study did test for CpH methylation, we cannot rule out 255 
the role of this epigenetic modification between the genotypes or indeed CpC methylation in the CC 256 
genotype. Further, that our primers were specific to bisulphite DNA, we also cannot rule-out whether 257 
CpH methylation might have effected binding of primers and if hypermethylated sequences where CpN 258 
are also methylated, might have led to underestimating also CpG methylation.  259 
The role of DNA methylation in the regulation of IL-6 is well documented. For example in rheumatoid 260 
arthritis, DNA methylation at an IL-6-related CpG was altered in affected patients, and a negative 261 
relationship between DNA methylation and IL-6 mRNA levels was observed, suggesting a DNA 262 
methylation-dependent regulation of IL-6 transcription (Nile et al., 2008). A further study in AD brains 263 
has shown a progressive decrease in DNA methylation at the IL-6 promoter with disease progression 264 
(Nicolia et al., 2017). Here we show that rs1800795 alters a CpG site leading to changes in DNA 265 
methylation. We therefore predict that this adds a further level of regulation of the gene for this 266 
cytokine within the AD brain. Interestingly, we see a significant difference in methylation between 267 
genotypes in AD and controls. We suggest that changes in methylation during AD progression, 268 
dependent on genotype, together with alterations in transcription factors such as GATA-1, lead to GxE 269 
interactions at which an allele becomes a risk factor dependent on disease state. For example, binding 270 
of GATA-1 has been shown to be influenced by DNA methylation, such as at the EKLF promoter (Li et 271 
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al., 2018) and increased methylation at the IL-6 promoter has been linked to increased binding of the 272 
transcriptional epigenetic repressor MeCP2 (Dandrea et al., 2009). 273 
 274 
5. Conclussion  275 
In conclusion, we report that the regulation of IL-6 within the prefrontal cortex is influenced by a SNP 276 
previously associated with AD that alters DNA methylation and which may influence AD risk. These 277 
results add further evidence for a genetic-epigenetic and possible gene-environment regulation of the 278 
IL-6 gene within the AD brain. 279 
 280 
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Figure 1 - IL-6 protein levels between different AD neuropathology stages. A. IL-6 protein levels did not 449 
significantly differ between control (n=17) and AD (n=24) (p=0.784). B.  IL-6 protein levels were not 450 
found to be significantly different between BRAAK staging (P=0.564) n=61. C. No significant difference 451 
was found between IL-6 protein levels and THAL grouping (p = 0.320) n=62. D. No significant difference 452 
was found between IL-6 protein levels and CERAD stages (p = 0.719) n=62. Plots represent median and 453 
25th-75th percentiles with individual plots of each samples shown. 454 
 455 
Figure 2 - IL-6 mRNA levels between Control and AD. IL-6 mRNA levels in control group (n=17) and AD 456 
group (n=24) were not significant (p=0.749). Plots represent median and 25th-75th percentiles with 457 
individual plots of each samples shown. 458 
 459 
Figure 3 - Protein and mRNA levels of IL-6 between rs1800795 genotypes. A. IL-6 protein levels were 460 
significantly higher in CC (n=21) compared to CG/GG (n 41) (p = 0.034) genotypes. B. IL-6 mRNA levels 461 
between CC (n=23) and CG/GG (n= 41) genotypes do not significantly differ (p=0.459). Plots present 462 
median and 25th-75th percentiles with individual plots of all samples shown. 463 
 464 
Figure  4 - DNA Methylation at the IL-6 promoter between rs1800795 genotypes. CpG site 1 methylation 465 
did not significantly differ between genotypes (p=0.708). CpG site 2 (only present in the G allele carriers) 466 
did not differ. CpG site 3 methylations significantly different between genotypes CC and CG/GG p = 467 
0.0003. CpG site 4 methylation significantly different in genotypes (p = <0.0001). CC (n 15), CG (n27) 468 
and GG (n =3) error bars represent standard deviation. 469 
 470 
Figure 5 - DNA methylation levels at the IL-6 promoter in control and AD brains. DNA methylation at CpG 471 
sites 1 (p=0.241), 3 (p=0.052) and 4 (p=0.625) (control n=8; AD n=17) and CpG site 2 (p=0.309) (control 472 
n=5; AD n=10). Error bars represent standard deviation.  473 
 474 
